IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.
Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.
Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.
Comparing Quadruplet Combination Treatment Regimens in NDMM
The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.
Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.
Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.
Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.
Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.
Treatment Approaches in Transplant-Eligible NDMM
Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.
GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).
